Mechanisms of oligodendrocyte interaction with normal human serum - defining the role of complement

Journal of the Neurological Sciences

Volumn 108, Issue 1, 1992, Pages 65-72

  Zajicek, J ^a   Wing, M G ^b   Lachmann, P J ^b   Compston, D A S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Complement; Complement regulatory protein; Demyelination; Multiple sclerosis; Oligodendrocyte

Indexed keywords

COMPLEMENT;

ANIMAL CELL; ARTICLE; DEMYELINATION; HUMAN; MULTIPLE SCLEROSIS; NEWBORN; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; RAT; SERUM;

ANIMAL; ANIMALS, NEWBORN; ASTROCYTES; BLOOD PHYSIOLOGY; BLOOD-BRAIN BARRIER; CELLS, CULTURED; COMPARATIVE STUDY; COMPLEMENT 1; COMPLEMENT 3; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT PATHWAY, CLASSICAL; DEMYELINATING DISEASES; OLIGODENDROGLIA; RATS; RATS, INBRED STRAINS; SUPPORT, NON-U.S. GOV'T;

EID: 0026508748     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0022-510X(92)90189-R     Document Type: Article

References (44)

1. Growth of a rat neuroblastoma cell line in a serum-free supplemented medium
2. Role of complement in demyelination in vitro by multiple sclerosis serum and other neurological disease sera
3. The pathogenesis of demyelinating disease: insights from cell biology
4. Lysis of RNA tumour viruses by human serum: direct antibody-independent triggering of classical complement pathway
5. Antibody-independent complement activation by myelin via the classical complement pathway
6. CD59, an Ly-6 like protein expressed in human lymphoid cells regulates the activation of the complement membrane attack complex on homologous cells
7. The relationship between the binding ability and the rate of activation of the complement component
8. The inactivated form of the first component of human complement
9. Multiple sclerosis: serum gamma globulin and demyelination in organ culture
10. Complement technology
11. Effect of chemical and enzymatic radioiodination on in vitro human Clq activities
12. Myelotoxicity of serum and spinal fluid in multiple sclerosis: a critical assessment
13. The binding and activation of the Clr-Cls subunit of the first component of human complement
14. Immunofluorescence demonstration of 2′:3′-cyclic-nucleotide 3′ phosphodiesterase in cultured oligodendrocytes of mouse, rat, calf and human
15. Endogenous association of decay accelerating factor (DAF) with C4b and C3b on cell membranes
16. Reactive lysis: the complement-mediated lysis of unsensitised cells. II. The characterisation of the activated reactor as C56 and the participation of C8 and C9
17. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
18. B cells and antibody in MS
19. Antibody-independent activation of C1 the first component of complement
20. Antibody-independent activation of the classical pathway of complement by Epstein-Barr virus
21. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue
22. Lessons from magnetic resonance imaging in multiple sclerosis
23. Inhibition of complement activation on the surface of cells after incorporation of decay accelerating factor (DAF) into their membranes
24. Human protectin (CD59), an 18,000–20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers
25. Anti-myelin basic protein and anti-myelin antibody-producing cells in multiple sclerosis
26. Propidium iodide labelling of dead cells
27. In vitro study of a reaction between the complement system and cellelar DNA
28. Antibody-independent activation of human C1 after interaction with heart subcellular membrane
29. The neuropathology of multiple sclerosis
30. A glial progenitor that develops in vitro into an astrocyte or an oligodencyte-depending culture medium
31. Development of oligodendrocytes and Schwann cell studied with a monoclonal antibody against galactocerebroside
32. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor
33. Normal rat serum cytotoxicity against syngeneic oligodendrocytes complement activation and attack in the absence of anti-myelin antibodies
34. Oligodendrocyte-macrophage interactions in vitro triggered by specific antibodies
35. Functional properties of membrane cofactor protein of complement
36. Tissue culture demyelination by normal human serum
37. Activation of complement on the surface of cells infected by human immunodefeciency virus
38. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement channels
39. Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies
40. Activation of complement by myelin: identification of C1-binding proteins by human myelin from central nervous tissue
41. Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody
42. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls
43. Isolation of a human erythrocytes membrane protein capable of inhibiting expression of homologous complement transmembrane channels